Related Experiment Video
Updated: Jul 10, 2026
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
[Care of patients after coronary stent implantation: what is important in practice?]
1Med. Klinik III - Kardiologie, Klinikum der J W Goethe Universität, Theodor-Stern-Kai 7, Frankfurt, Germany. schaechinger@em.uni-frankfurt.de
Insights
Drug-eluting stents reduce restenosis but may increase late stent thrombosis. Prolonged dual antiplatelet therapy is often recommended, emphasizing patient compliance and risk factor management for better outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Drug-eluting stents (DES) significantly reduce restenosis after coronary stent implantation.
- However, DES implantation is associated with an increased risk of late stent thrombosis (>30 days).
- Current evidence on the extent and duration of this risk remains inconclusive.
Purpose of the Study:
- To review the current understanding of stent thrombosis and cardiovascular risks associated with DES.
- To provide guidance on dual antiplatelet therapy duration and management in patients undergoing DES implantation.
- To highlight the importance of managing cardiovascular risk factors post-stent implantation.
Main Methods:
- Review of current literature and clinical guidelines on drug-eluting stents, stent thrombosis, and antiplatelet therapy.
- Analysis of data regarding the duration and risks of dual antiplatelet therapy.
- Discussion of management strategies for cardiovascular risk factors.
Main Results:
- Dual antiplatelet therapy (aspirin and clopidogrel) is recommended for 12 months post-DES implantation, especially in high-risk patients.
- Premature discontinuation of dual antiplatelet therapy should be avoided; many procedures can be performed under therapy.
- Patients on triple therapy (aspirin, clopidogrel, coumarin) face an increased bleeding risk and require careful monitoring.
- Risk factor management (hyperlipidemia, hypertension, diabetes mellitus) is crucial post-stent implantation.
- Screening for diabetes mellitus is important, as many patients have undiagnosed diabetes or glucose intolerance.
Conclusions:
- DES offer benefits in reducing restenosis but necessitate careful management of stent thrombosis risks.
- Optimizing dual antiplatelet therapy duration and ensuring patient compliance are key to mitigating risks.
- Comprehensive medical management of underlying cardiovascular risk factors is essential for long-term patient outcomes.
Abstract:
The introduction of Drug Eluting Stents was an important step to reduce restenosis rate after coronary stent implantation. Unfortunately, reduction of restenosis was paid off by the price of potential increased late (>30 days) stent thrombosis. However, current data are not completely conclusive with respect to extent and duration of stent thrombosis and cardiovascular risk after drug eluting stent implantation. Until now, especially for patients at risk for stent thrombosis a prolonged (12 instead of 6 months) dual antiplatelet therapy with aspirin and clopidogrel is recommended. Thereby, the quality of physician instructions is predictive for patient's compliance. Premature termination of dual antiplatelet therapy should be avoided; many small surgical interventions (e.g. tooth extraction) can be performed under dual antiplatelet therapy. Patients with "triple therapy" (aspirin, clopidogrel and coumarin derivate) should be monitored carefully, since they have an excessive bleeding risk. An elective coronary angiography after coronary stent implantation is not routinely necessary. However in selected high-risk patients (e.g. left main or multivessel stent implantation) control angiography may be useful. Medical therapy of risk factors (hyperlipidemia, hypertension, and diabetes mellitus) is essential also after coronary stent implantation. It is important to screen patients for diabetes mellitus, since approximately 1/3 of patients after coronary intervention have an otherwise unrecognized diabetes mellitus or glucose tolerance disturbance.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Cardiac Catheterization IV: Nursing Management
01:26Acute Coronary Syndrome V: Nursing Management
01:20Angina V: Nursing Management
01:23Peripheral Artery Disease V: Postoperative Nursing Management